Generation of Human Anti-Tumor Monoclonal Antibodies

Brams, Peter

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: First Independent Research Support & Transition (FIRST) Awards (R29)
• Project #: 5R29CA064034-04
• Application #: 2106249
• Study Section: Experimental Immunology Study Section (EI)
• Project Start: 1993-09-24
• Project End: 1998-08-31
• Budget Start: 1996-09-01
• Budget End: 1997-08-31
• Support Year: 4
• Fiscal Year: 1996

Institution

• Name: Idec Pharmaceuticals Corporation
• City: San Diego
• State: CA
• Country: United States
• Zip Code: 92121

Publications

Chamat, S; Walsh, E E; Anderson, D et al. (1999) Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus. J Infect Dis 180:268-77

Coccia, M A; Brams, P (1998) High titer, prostate specific antigen-specific human IgG production by hu-PBL-SCID mice immunized with antigen-mouse IgG2a complex-pulsed autologous dendritic cells. J Immunol 161:5772-80

Brams, P; Nguyen, M L; Chamat, S et al. (1998) Antigen-specific IgG responses from naive human splenocytes: in vitro priming followed by antigen boost in the SCID mouse. J Immunol 160:2051-8